CN111557968A - A kind of traditional Chinese medicine compound composition and application with regulating immune function - Google Patents
A kind of traditional Chinese medicine compound composition and application with regulating immune function Download PDFInfo
- Publication number
- CN111557968A CN111557968A CN202010187232.8A CN202010187232A CN111557968A CN 111557968 A CN111557968 A CN 111557968A CN 202010187232 A CN202010187232 A CN 202010187232A CN 111557968 A CN111557968 A CN 111557968A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- water
- compound composition
- astragalus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- 230000001105 regulatory effect Effects 0.000 title claims description 14
- 230000036737 immune function Effects 0.000 title claims description 13
- 235000006533 astragalus Nutrition 0.000 claims abstract description 28
- 241001061264 Astragalus Species 0.000 claims abstract description 27
- 210000004233 talus Anatomy 0.000 claims abstract description 27
- 241000208340 Araliaceae Species 0.000 claims abstract description 26
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 26
- 235000008434 ginseng Nutrition 0.000 claims abstract description 26
- 241000132012 Atractylodes Species 0.000 claims abstract description 22
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 21
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 19
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 8
- 230000036039 immunity Effects 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 239000000284 extract Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- 241000222336 Ganoderma Species 0.000 claims 4
- 244000303040 Glycyrrhiza glabra Species 0.000 claims 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 4
- 235000011477 liquorice Nutrition 0.000 claims 4
- 241000915604 Scutellaria barbata Species 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 241000045403 Astragalus propinquus Species 0.000 claims 1
- 239000009636 Huang Qi Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 34
- 210000000952 spleen Anatomy 0.000 abstract description 33
- 210000004698 lymphocyte Anatomy 0.000 abstract description 19
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 17
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 17
- 229940010454 licorice Drugs 0.000 abstract description 17
- 239000010072 ban-zhi-lian Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 9
- 238000005728 strengthening Methods 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 8
- 230000007812 deficiency Effects 0.000 abstract description 6
- 102000000588 Interleukin-2 Human genes 0.000 abstract description 4
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 235000008216 herbs Nutrition 0.000 abstract description 3
- 230000003832 immune regulation Effects 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 241000202807 Glycyrrhiza Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 240000002853 Nelumbo nucifera Species 0.000 description 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000004073 interleukin-2 production Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有调节免疫功能的中药复方组合物与应用,由以下重量配比的原料组成:黄芪25‑35g,人参5‑15g,灵芝5‑15g,半枝莲10‑20g,白术10‑20g,甘草10‑20g。本发明提供的中药复方组合物配方中,黄芪与人参共为君药,补气升阳,复脉固脱;灵芝与白术均能健脾益气、扶助正气共为臣药,半枝莲辅佐黄芪、人参提高人体免疫力,又可牵制芪参温热、抗肿瘤,为佐药,甘草补中益气调和诸药为使药。上述六味药相辅相成,具有扶正祛邪、补虚功效,现代药理表明,本发明中药复方组合物能够增脾淋巴细胞的重量,提高脾淋巴细胞的增殖及IL‑2分泌水平,从而达到增强肿瘤患者免疫力的效果,延长肿瘤患者的生存期,提高生存质量。The invention discloses a traditional Chinese medicine compound composition and application with immune regulation function, which is composed of the following raw materials by weight: 25-35 g of astragalus, 5-15 g of ginseng, 5-15 g of Ganoderma lucidum, 10-20 g of Banzhilian, 10-20 g of Atractylodes Rhizoma 10‑20g, licorice 10‑20g. In the traditional Chinese medicine compound composition formula provided by the present invention, astragalus and ginseng are the monarch medicine, tonifying qi and raising yang, and strengthening the pulse; Ganoderma lucidum and atractylodes can both strengthen the spleen and replenish qi, and support the righteousness, and are the minister medicine, and Banzhilian is the auxiliary medicine. Astragalus and ginseng can improve the body's immunity, and can restrain the heat and anti-tumor of Astragalus, as adjuvant. The above-mentioned six herbs complement each other and have the effects of strengthening the body and eliminating pathogenic factors, as well as tonifying deficiency. Modern pharmacology shows that the traditional Chinese medicine compound composition of the present invention can increase the weight of spleen lymphocytes, improve the proliferation of spleen lymphocytes and the level of IL-2 secretion, thereby enhancing tumor patients. The effect of immunity, prolong the survival period of tumor patients and improve the quality of life.
Description
技术领域technical field
本发明涉及中药技术领域,具体涉及一种具有调节免疫功能的中药复方组合物与应用。The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine compound composition and application with an immune-regulating function.
背景技术Background technique
肿瘤目前的治疗主要以西医治疗为主,手术、化疗、放疗、靶向治疗、免疫治疗等,但是手术经常有并发症,化放疗经常有毒副作用。中医理论认为阴阳失衡、正虚邪盛是肿瘤发生发展的关键原因。调整阴阳、扶正祛邪是肿瘤治疗的重点。中医强调通过调整阴阳、扶助正气达到阴平阳秘、正气充足的机体平衡状态,,从而实现控制肿瘤生长、改善患者临床症状、提高患者生活质量等目的。The current treatment of tumors is mainly based on Western medicine, such as surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. However, surgery often has complications, and chemotherapy and radiotherapy often have toxic and side effects. The theory of traditional Chinese medicine believes that the imbalance of yin and yang and the prosperity of positive and deficient evil are the key reasons for the occurrence and development of tumors. Adjusting yin and yang, strengthening the righteousness and eliminating pathogenic factors are the key points of tumor treatment. Traditional Chinese medicine emphasizes that by adjusting yin and yang, and supporting righteousness to achieve a balance between yin and yang, and sufficient righteousness, so as to achieve the purpose of controlling tumor growth, improving patients' clinical symptoms, and improving patients' quality of life.
因此,研发一种具有扶正祛邪、补虚功效,以调节患者的免疫功能达到抑制患者肿瘤细胞生长的作用的中药是及其必要的。Therefore, it is extremely necessary to develop a traditional Chinese medicine with the functions of strengthening the body and eliminating pathogenic factors and tonic for deficiency, so as to regulate the immune function of the patient and inhibit the growth of the patient's tumor cells.
发明内容SUMMARY OF THE INVENTION
本发明针对以上问题提供了一种具有调节免疫功能的中药复方组合物,具有扶正祛邪、补虚功效,通过调节患者的免疫功能达到抑制患者肿瘤细胞生长的作用,延长患者的生命,提高生活质量。In view of the above problems, the present invention provides a traditional Chinese medicine compound composition with regulating immune function. quality.
本发明的目的是通过以下技术方案实现的:The purpose of this invention is to realize through the following technical solutions:
一种具有调节免疫功能的中药复方组合物,由以下重量配比的原料组成:黄芪25-35g,人参5-15g,灵芝5-15g,半枝莲10-20g,白术10-20g,甘草10-20g。A traditional Chinese medicine compound composition with immune regulation function, which is composed of the following raw materials by weight: 25-35g of Astragalus, 5-15g of Ginseng, 5-15g of Ganoderma Lucidum, 10-20g of Banzhilian, 10-20g of Atractylodes Rhizoma, 10g of Licorice -20g.
优选地,所述调节免疫功能的中药复方组合物,由以下重量配比的原料组成:黄芪30g,人参10g,灵芝10g,半枝莲15g,白术15g,甘草10g。Preferably, the traditional Chinese medicine compound composition for regulating immune function is composed of the following raw materials by weight: Astragalus 30g, Ginseng 10g, Ganoderma lucidum 10g, Banzhilian 15g, Atractylodes Rhizoma 15g, and Licorice 10g.
优选地,所述调节免疫功能的中药复方组合物,由以下重量配比的原料组成:黄芪25g,人参5g,灵芝5g,半枝莲10g,白术10g,甘草15g。Preferably, the traditional Chinese medicine compound composition for regulating immune function is composed of the following raw materials by weight: Astragalus 25g, ginseng 5g, Ganoderma lucidum 5g, Banzhilian 10g, Atractylodes 10g, and licorice 15g.
本发明还提供了调节免疫功能的中药复方组合物在制备抗肿瘤中药制剂的应用,所述中药制剂为汤剂、颗粒剂、片剂或丸剂。The invention also provides the application of the traditional Chinese medicine compound composition for regulating immune function in the preparation of anti-tumor traditional Chinese medicine preparations, wherein the traditional Chinese medicine preparations are decoctions, granules, tablets or pills.
优选地,所述汤剂的制备方法如下:Preferably, the preparation method of described decoction is as follows:
1)按比例,将黄芪、人参、灵芝、半枝莲、白术、甘草加水煎煮提取3次,每次40-60min,第一次加8-12倍量水,第二次加6-10倍量水,第三次加4-8倍量水,得混合液;1) According to the proportion, decoct and extract astragalus, ginseng, Ganoderma lucidum, bark lotus, Atractylodes Rhizoma, and licorice for 3 times, 40-60min each time, add 8-12 times the amount of water for the first time, and add 6-10 times the amount of water for the second time. times the amount of water, add 4-8 times the amount of water for the third time to obtain a mixed solution;
2)将所述混合液经500-550目筛过滤后经高温灭菌装瓶即得目标物。2) The mixed solution is filtered through a 500-550 mesh sieve and then sterilized and bottled at high temperature to obtain the target substance.
优选地,所述颗粒剂、片剂或丸剂的制备方法如下:Preferably, the preparation method of described granule, tablet or pill is as follows:
S1、按比例将黄芪、人参、灵芝、半枝莲、白术、甘草加水煎煮提取3次,每次40-60min,第一次加8-12倍量水,第二次加6-10倍量水,第三次加4-8倍量水,将提取液滤过,合并滤液,浓缩至相对密度1.30~1.35的浸膏;S1. Decoct and extract astragalus, ginseng, ganoderma lucidum, bark lotus, Atractylodes rhizome, and licorice in proportion for 3 times, 40-60min each time, add 8-12 times the amount of water for the first time, and add 6-10 times the amount of water for the second time. amount of water, add 4-8 times the amount of water for the third time, filter the extract, combine the filtrates, and concentrate to an extract with a relative density of 1.30-1.35;
S2、在浸膏中加入辅料,混匀,加75%乙醇0~100ml制粒,60℃~65℃干燥,制成颗粒剂、片剂或丸剂。S2. Add excipients to the extract, mix well, add 0-100ml of 75% ethanol to granulate, and dry at 60°C to 65°C to prepare granules, tablets or pills.
优选地,所述辅料为以下重量配比的物质:15-25g蔗糖粉和70g~75g糊精。Preferably, the auxiliary materials are substances in the following weight ratios: 15-25g sucrose powder and 70g-75g dextrin.
方解:Solution:
黄芪:味甘,主入肺、脾、心经,有补气升阳、益卫固表、利水消肿、托毒生肌的作用,具有增强心脏功能、提高人体免疫力、抗衰老、抗菌功效。Astragalus: sweet, mainly enters the lung, spleen, and heart meridians, has the functions of invigorating qi and raising yang, invigorating the body and strengthening the table, diuretic and swelling, and nourishing the muscles. It can enhance heart function, improve human immunity, anti-aging, and antibacterial effects. .
人参:性平、味甘、微苦,微温。归脾、肺经、心经。功效:大补元气,复脉固脱,补脾益肺,生津止渴,安神益智。主治:劳伤虚损、一切气血津液不足之症。Ginseng: flat, sweet, slightly bitter, slightly warm. Returns the spleen, lung, and heart meridians. Efficacy: invigorating vitality, strengthening the pulse, invigorating the spleen and benefiting the lung, promoting body fluid and quenching thirst, soothing the mind and improving wisdom. Indications: overwork injury, deficiency of qi, blood and body fluid.
灵芝:益气血,安心神,健脾胃。主治虚劳,心悸,失眠,头晕,神疲乏力,久咳气喘,冠心病,矽肺,肿瘤。Ganoderma lucidum: nourishes qi and blood, reassures the mind, and strengthens the spleen and stomach. Indications for consumptive fatigue, palpitations, insomnia, dizziness, fatigue, chronic cough and asthma, coronary heart disease, silicosis, and tumors.
白术:味甘苦,性温,归于脾、胃二经。主要的功效是益气健脾、燥湿利水、止汗安胎,可以用于治疗脾气虚诸症,可以健脾燥湿,主要用于脾虚而引起的食少便溏、泄泻、痰饮、水肿诸症,可以用于治疗因脾虚中阳不正而引起的痰饮内停、痰湿中煮等病症。Atractylodes: sweet and bitter in taste, warm in nature, belonging to the spleen and stomach meridians. The main functions are to invigorate Qi and invigorate the spleen, dry dampness and diuretic water, stop sweating and soothe the miscarriage. It can be used to treat spleen deficiency and other symptoms. It can invigorate the spleen and dry dampness. It can be used to treat phlegm-drinking internal stoppage and phlegm-dampness boiling in spleen caused by spleen deficiency and yang disorder.
半枝莲:味辛、寒,性平。归肺经、肝经、肾经。具有清热解毒,活血化瘀,消肿止痛,抗癌之功效;治阑尾炎、肝炎、胃痛、早期肝癌、肺癌、子宫颈癌、乳腺炎等;外用治痛疖疗,跌打肿痛等症。Banzhilian: Pungent in taste, cold in nature, flat in nature. Returns the lung, liver, and kidney meridians. It has the functions of clearing away heat and detoxifying, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and anti-cancer; it can treat appendicitis, hepatitis, stomach pain, early liver cancer, lung cancer, cervical cancer, mastitis, etc.;
甘草补中益气调和诸药为使药。Licorice tonifies the middle and replenishes the Qi and harmonizes the various medicines as the medicine.
本方中,黄芪与人参共为君药,补气升阳,复脉固脱;灵芝与白术均能健脾益气、扶助正气共为臣药,半枝莲辅佐黄芪、人参提高人体免疫力,又可牵制芪参温热、抗肿瘤,为佐药,甘草补中益气调和诸药为使药;上述六味药相辅相成,扶正祛邪。In this recipe, astragalus and ginseng are the monarch medicine, tonifying qi and raising yang, and strengthening the pulse; both Ganoderma lucidum and Atractylodes can strengthen the spleen and qi, and support righteousness. , and can contain Qishen warm, anti-tumor, as an adjuvant, licorice tonifying Qi and reconciling various medicines as the medicine; the above six herbs complement each other, strengthen the righteousness and dispel pathogens.
本发明提供的中药复方组合物对肿瘤机体的免疫力影响参见以下试验:The immune influence of the traditional Chinese medicine compound composition provided by the present invention on the tumor body refers to the following test:
试验方法:experiment method:
一、H22荷瘤小鼠模型的建立、分组和给药1. Establishment, grouping and administration of H22 tumor-bearing mouse model
选取接种8天S180鼠源小鼠,腹部皮肤消毒后,抽取腹水,离心后,弃上清,PBS调细胞浓度为1×106个/ml,每次小鼠右侧腋部皮下接种0.2ml,次日将接种的小鼠随机分为4组,分别为荷瘤模型组、CTX阳性组、本发明中药复方组合物和CTX联合复方黄芪口服液组,每组8只。CTX阳性组腹腔注射环磷酰胺30mg/kg,本发明中药复方组合物以汤剂形式以100mg/kg剂量灌胃给药。CTX联合本发明中药复方组合物组在腹腔注射环磷酰胺30mg/kg基础,灌胃100mg/kg。荷瘤模型组灌胃等体积的生理盐水,每日一次,连续16天。末次给药24h后,脱颈椎处死小鼠,剥离肿瘤组织,称重并计算肿瘤抑制率:瘤重抑制率(%)=(对照组平均瘤重-治疗组平均瘤重)/对照组平均瘤重×100%。S180 mouse-derived mice were selected for 8 days of inoculation. After the abdominal skin was disinfected, ascites was extracted, and the supernatant was discarded after centrifugation. On the next day, the inoculated mice were randomly divided into 4 groups, namely the tumor-bearing model group, the CTX positive group, the traditional Chinese medicine compound composition of the present invention and the CTX combined with compound astragalus oral liquid group, with 8 mice in each group. The CTX positive group was intraperitoneally injected with cyclophosphamide 30 mg/kg, and the traditional Chinese medicine compound composition of the present invention was administered by gavage at a dose of 100 mg/kg in the form of decoction. The CTX combined with the traditional Chinese medicine compound composition group of the present invention was given intraperitoneal injection of cyclophosphamide at 30 mg/kg and 100 mg/kg by gavage. The tumor-bearing model group was given an equal volume of normal saline, once a day, for 16 consecutive days. 24h after the last administration, the mice were sacrificed by de-cervical vertebrae, the tumor tissue was stripped, weighed and the tumor inhibition rate was calculated: tumor weight inhibition rate (%)=(average tumor weight of control group-average tumor weight of treatment group)/average tumor weight of control group Weight × 100%.
1、脾淋巴细胞的制备1. Preparation of spleen lymphocytes
小鼠脱脊椎处死,无菌取其脾脏。将脾脏用玻璃片磨碎,过膜,于1200rpm离心5分钟。弃去上清,沉淀加入红细胞裂解液(每个脾脏约1ml),混匀,静置1分钟,加入PBS,离心。再加入PBS,过膜,离心。将所剩细胞洗涤1-2次后,用含10%FBS的RPMI-1640将细胞调至所需浓度。Mice were sacrificed by vertebral dissection, and their spleens were removed aseptically. The spleen was triturated with a glass slide, passed through a membrane, and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded, red blood cell lysate (about 1 ml per spleen) was added to the pellet, mixed well, allowed to stand for 1 minute, added with PBS, and centrifuged. Then add PBS, pass through membrane, and centrifuge. After washing the remaining cells 1-2 times, the cells were adjusted to the desired concentration with RPMI-1640 containing 10% FBS.
2、脾淋巴细胞增殖功能的检测2. Detection of spleen lymphocyte proliferation function
各组脾淋巴细胞接种于96孔板(4×105个/孔),同时加入2.5μg/ml ConA进行刺激,细胞于含5%CO2培养箱中培养48h,MTT法测定各组脾淋巴细胞的增殖情况。The spleen lymphocytes in each group were inoculated into 96-well plates (4×10 5 cells/well), and 2.5 μg/ml ConA was added for stimulation. The cells were cultured in a 5% CO2 incubator for 48 hours, and the splenic lymphocytes in each group were measured by MTT method. proliferation.
3、酶联免疫吸附法检测IL-2产生水平3. Enzyme-linked immunosorbent assay to detect the level of IL-2 production
各组脾淋巴细胞接种于96孔板(4×105个/孔),同时加入2.5μg/ml ConA进行刺激,细胞于含5%CO2培养箱中培养16h,收集培养上清,酶联免疫吸附法检测,检测培养上清细胞因子产生水平。Spleen lymphocytes in each group were inoculated into 96-well plates (4×10 5 cells/well), and 2.5 μg/ml ConA was added to stimulate them. The cells were cultured in a 5% CO2 incubator for 16 h, and the culture supernatant was collected. Adsorption method was used to detect the cytokine production level in the culture supernatant.
二、试验结果2. Test results
1、本发明中药复方组合物对H22荷瘤小鼠淋巴细胞脾重的影响1. Influence of the traditional Chinese medicine compound composition of the present invention on the lymphocyte spleen weight of H22 tumor-bearing mice
表1结果显示,药物干预16天后,分离脾脏,称重;结果显示,与荷瘤模型组小鼠比较,化疗药物环磷酰胺组脾脏显著低于荷瘤模型组小鼠,差异有显著性意义;与化疗药物环磷酰胺组比较,本发明中药复方组合物汤剂药物干预显著提高环磷酰胺组小鼠脾脏重量,提示本发明中药复方组合物对免疫器官有一定的作用。The results in Table 1 show that after 16 days of drug intervention, the spleen was isolated and weighed; the results showed that, compared with the mice in the tumor-bearing model group, the spleen of the chemotherapy drug cyclophosphamide group was significantly lower than that of the mice in the tumor-bearing model group, and the difference was significant. Compared with the chemotherapeutic drug cyclophosphamide group, the traditional Chinese medicine compound composition decoction drug intervention of the present invention significantly increased the spleen weight of the mice in the cyclophosphamide group, suggesting that the traditional Chinese medicine compound composition of the present invention has a certain effect on immune organs.
表1.发明中药组合物汤剂对H22荷瘤小鼠淋巴细胞脾重的影响(n=8)Table 1. the influence of invention Chinese medicine composition decoction on lymphocyte spleen weight of H22 tumor-bearing mice ( n=8)
与荷瘤模型组比较:*P﹤0.05,**P﹤0.01;与环磷酰胺组比较#P﹤0.05,##P﹤0.01Compared with the tumor-bearing model group: * P﹤0.05, ** P﹤0.01; compared with the cyclophosphamide group # P﹤0.05, ## P﹤0.01
2、本发明中药复方组合物对H22荷瘤小鼠淋巴细胞增殖功能的影响2. Influence of the traditional Chinese medicine compound composition of the present invention on the proliferation function of lymphocytes in H22 tumor-bearing mice
表2结果显示,药物干预16天后,分离各组脾淋巴细胞,T淋巴细胞在ConA的诱导下发生克隆性增殖,从而诱导T淋巴细胞增殖;MTT检测结果显示,与环磷酰胺组比较,本发明中药复方组合物干预组或联合用药组OD值显著高于荷瘤模型组,差异均有显著意义(P﹤0.01);与环磷酰胺化疗组比较,本发明中药复方组合物联合环磷酰胺用药组OD值显著提高,差异具有显著性意义(P﹤0.01)。The results in Table 2 show that after 16 days of drug intervention, spleen lymphocytes were isolated from each group, and T lymphocytes were cloned under the induction of ConA, thereby inducing T lymphocyte proliferation; MTT test results showed that compared with the cyclophosphamide group, this The OD value of the traditional Chinese medicine compound composition intervention group or the combined drug group of the present invention was significantly higher than that of the tumor-bearing model group, and the differences were all significant (P﹤0.01). The OD value of the medication group was significantly increased, and the difference was significant (P﹤0.01).
表2.本发明中药复方组合物组对H22荷瘤小鼠淋巴细胞增殖功能的影响(n=8)Table 2. the effect of traditional Chinese medicine compound composition group of the present invention on lymphocyte proliferation function of H22 tumor-bearing mice ( n=8)
与荷瘤模型组比较:*P﹤0.05,**P﹤0.01;与环磷酰胺组比较#P﹤0.05,##P﹤0.01Compared with the tumor-bearing model group: * P﹤0.05, ** P﹤0.01; compared with the cyclophosphamide group # P﹤0.05, ## P﹤0.01
3、本发明中药复方组合物对H22荷瘤小鼠淋巴细胞IL-2产生的影响3. The effect of the traditional Chinese medicine compound composition of the present invention on the production of IL-2 in lymphocytes of H22 tumor-bearing mice
表3结果显示,与荷瘤模型组小鼠比较,环磷酰胺药物干预显著抑制脾淋巴细胞IL-2产生水平;与环磷酰胺药物干预组比较,本发明中药干预组或联合用药组小鼠脾淋巴细胞IL-2产生水平显著高于对照组。The results in Table 3 show that, compared with the tumor-bearing model group of mice, cyclophosphamide drug intervention significantly inhibited the level of IL-2 production in spleen lymphocytes; The level of IL-2 production in spleen lymphocytes was significantly higher than that in the control group.
表3.本发明中药复方组合物对H22荷瘤小鼠脾淋巴细胞IL-2产生水平的影响(n=8)Table 3. the effect of Chinese medicine compound composition of the present invention on H22 tumor-bearing mouse spleen lymphocyte IL-2 production level ( n=8)
与荷瘤模型组比较:*P﹤0.05,**P﹤0.01;与环磷酰胺组比较#P﹤0.05,##P﹤0.01Compared with the tumor-bearing model group: * P﹤0.05, ** P﹤0.01; compared with the cyclophosphamide group # P﹤0.05, ## P﹤0.01
以上结果表明,本发明中药复方组合物能够显著提高脾淋巴细胞的增殖及IL-2分泌水平,从而增强荷瘤小鼠机体的肿瘤免疫力。The above results show that the traditional Chinese medicine compound composition of the present invention can significantly improve the proliferation of spleen lymphocytes and the level of IL-2 secretion, thereby enhancing the tumor immunity of tumor-bearing mice.
本发明的有益效果为:本发明提供的中药复方组合物本方中,黄芪与人参共为君药,补气升阳,复脉固脱;灵芝与白术均能健脾益气、扶助正气共为臣药,半枝莲辅佐黄芪、人参提高人体免疫力,又可牵制芪参温热、抗肿瘤,为佐药,甘草补中益气调和诸药为使药。上述六味药相辅相成,具有扶正祛邪、补虚功效;现代药理表明,本发明中药复方组合物能够增脾淋巴细胞的重量,提高脾淋巴细胞的增殖及IL-2分泌水平,从而达到增强肿瘤患者免疫力的效果,延长肿瘤患者的生存期,提高生存质量。The beneficial effects of the present invention are as follows: in the traditional Chinese medicine compound composition provided by the present invention, astragalus and ginseng are the monarch medicine, tonifying qi and raising yang, and strengthening the pulse; As a ministerial medicine, Banzhilian assists Astragalus and Ginseng to improve human immunity, and can also contain Astragalus, warm and anti-tumor. The above-mentioned six herbs complement each other, and have the effects of strengthening the body and eliminating pathogens, and tonic for deficiency; modern pharmacology shows that the traditional Chinese medicine compound composition of the present invention can increase the weight of spleen lymphocytes, improve the proliferation of spleen lymphocytes and the level of IL-2 secretion, thereby enhancing tumor patients. The effect of immunity, prolong the survival period of tumor patients and improve the quality of life.
具体实施方式Detailed ways
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。The present invention is further described below by way of examples, but the present invention is not limited to the scope of the described examples.
实施例1Example 1
一种具有调节免疫功能的中药复方组合物,由以下重量配比的原料组成:黄芪30g,人参10g,灵芝10g,半枝莲15g,白术15g,甘草10g。A traditional Chinese medicine compound composition with the function of regulating immunity is composed of the following raw materials by weight: astragalus 30g, ginseng 10g, ganoderma lucidum 10g, bark lotus 15g, atractylodes 15g, licorice 10g.
将黄芪30g,人参10g,灵芝10g,半枝莲15g,白术15g,甘草10g加水煎煮提取3次,每次50min,第一次加10倍量水,第二次加8倍量水,第三次加6倍量水,得混合液;将所述混合液经500目筛过滤后经高温灭菌装瓶制得具有调节免疫功能的汤剂。Add 30g of Astragalus, 10g of ginseng, 10g of Ganoderma lucidum, 15g of Banzhilian, 15g of Atractylodes Rhizoma, and 10g of Licorice with water and decocted and extracted 3 times, 50min each time, add 10 times the amount of water for the first time, add 8 times the amount of water for the second time, and then add 8 times the amount of water for the second time. Add 6 times the amount of water three times to obtain a mixed solution; filter the mixed solution through a 500-mesh sieve, then sterilize and bottle at high temperature to prepare a decoction with an immune-regulating function.
将黄芪30g,人参10g,灵芝10g,半枝莲15g,白术15g,甘草10g加水煎煮提取3次,每次50min,第一次加10倍量水,第二次加8倍量水,第三次加6倍量水,将提取液经500目筛滤过,合并滤液,浓缩至相对密度1.32的浸膏;在浸膏中加入20g蔗糖粉和72g糊精,混匀,加75%乙醇60ml制粒,63℃干燥,制成颗粒剂、片剂或丸剂。Add 30g of Astragalus, 10g of ginseng, 10g of Ganoderma lucidum, 15g of Banzhilian, 15g of Atractylodes Rhizoma, and 10g of Licorice with water and decocted and extracted 3 times, 50min each time, add 10 times the amount of water for the first time, add 8 times the amount of water for the second time, and then add 8 times the amount of water for the second time. Add 6 times the amount of water three times, filter the extract through a 500-mesh sieve, combine the filtrates, and concentrate to an extract with a relative density of 1.32; add 20g sucrose powder and 72g dextrin to the extract, mix well, and add 75% ethanol 60ml is granulated and dried at 63°C to make granules, tablets or pills.
实施例2Example 2
一种具有调节免疫功能的中药复方组合物,由以下重量配比的原料组成:黄芪25g,人参5g,灵芝5g,半枝莲10g,白术10g,甘草15g。A traditional Chinese medicine compound composition with immune regulation function is composed of the following raw materials by weight: 25 g of astragalus, 5 g of ginseng, 5 g of ganoderma lucidum, 10 g of bark lotus, 10 g of atractylodes, and 15 g of licorice.
将黄芪25g,人参5g,灵芝5g,半枝莲10g,白术10g,甘草15g加水煎煮提取3次,每次40min,第一次加8倍量水,第二次加6倍量水,第三次加4倍量水,得混合液;将所述混合液经520目筛过滤后经高温灭菌装瓶制得具有调节免疫功能的汤剂。Add 25g of Astragalus, 5g of ginseng, 5g of Ganoderma lucidum, 10g of Banzhilian, 10g of Atractylodes Rhizoma, and 15g of Licorice in water to extract 3 times, each 40min, add 8 times the amount of water for the first time, add 6 times the amount of water for the second time, Add 4 times the amount of water three times to obtain a mixed solution; filter the mixed solution through a 520-mesh sieve, then sterilize and bottle at high temperature to prepare a decoction with an immune-regulating function.
将黄芪25g,人参5g,灵芝5g,半枝莲10g,白术10g,甘草10g加水煎煮提取3次,每次40min,第一次加8倍量水,第二次加6倍量水,第三次加4倍量水,将提取液经500目筛滤过,合并滤液,浓缩至相对密度1.32的浸膏;在浸膏中加入15g蔗糖粉和70g糊精,混匀,加75%乙醇40ml制粒,60℃干燥,制成颗粒剂、片剂或丸剂。Add 25g of Astragalus, 5g of ginseng, 5g of Ganoderma lucidum, 10g of Banzhilian, 10g of Atractylodes Rhizoma, and 10g of Licorice in water to extract 3 times, 40min each time, add 8 times the amount of water for the first time, add 6 times the amount of water for the second time, Add 4 times the amount of water three times, filter the extract through a 500-mesh sieve, combine the filtrates, and concentrate to an extract with a relative density of 1.32; add 15g sucrose powder and 70g dextrin to the extract, mix well, and add 75% ethanol 40ml is granulated and dried at 60°C to make granules, tablets or pills.
实施例3Example 3
一种具有调节免疫功能的中药复方组合物,由以下重量配比的原料组成:A traditional Chinese medicine compound composition with regulating immune function, which is composed of the following raw materials by weight:
黄芪35g,人参15g,灵芝15g,半枝莲20g,白术20g、甘草20g。Astragalus 35g, Ginseng 15g, Ganoderma lucidum 15g, Banzhilian 20g, Atractylodes 20g, Licorice 20g.
将黄芪35g,人参15g,灵芝15g,半枝莲20g,白术20g、甘草20g加水煎煮提取3次,每次60min,第一次加12倍量水,第二次加10倍量水,第三次加8倍量水,得混合液;将所述混合液经550目筛过滤后经高温灭菌装瓶制得具有调节免疫功能的汤剂。Add 35g of Astragalus, 15g of ginseng, 15g of Ganoderma lucidum, 20g of Banzhilian, 20g of Atractylodes Rhizoma, and 20g of Licorice in water for 3 times, 60min each time, add 12 times the amount of water for the first time, add 10 times the amount of water for the second time, Add 8 times the amount of water three times to obtain a mixed solution; filter the mixed solution through a 550-mesh sieve, then sterilize and bottle at high temperature to prepare a decoction with an immune-regulating function.
将黄芪35g,人参15g,灵芝15g,半枝莲20g,白术20g,甘草20g加水煎煮提取3次,每次60min,第一次加12倍量水,第二次加10倍量水,第三次加8倍量水,将提取液经550目筛滤过,合并滤液,浓缩至相对密度1.35的浸膏;在浸膏中加入25g蔗糖粉和75g糊精,混匀,加75%乙醇100ml制粒,65℃干燥,制成颗粒剂、片剂或丸剂。Add 35g of Astragalus, 15g of ginseng, 15g of Ganoderma lucidum, 20g of Banzhilian, 20g of Atractylodes Rhizoma, and 20g of Licorice in water to extract 3 times, each time for 60min, add 12 times the amount of water for the first time, add 10 times the amount of water for the second time, Add 8 times the amount of water three times, filter the extract through a 550-mesh sieve, combine the filtrates, and concentrate to an extract with a relative density of 1.35; add 25g sucrose powder and 75g dextrin to the extract, mix well, and add 75% ethanol 100ml is granulated and dried at 65°C to make granules, tablets or pills.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010187232.8A CN111557968A (en) | 2020-03-17 | 2020-03-17 | A kind of traditional Chinese medicine compound composition and application with regulating immune function |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010187232.8A CN111557968A (en) | 2020-03-17 | 2020-03-17 | A kind of traditional Chinese medicine compound composition and application with regulating immune function |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111557968A true CN111557968A (en) | 2020-08-21 |
Family
ID=72069852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010187232.8A Pending CN111557968A (en) | 2020-03-17 | 2020-03-17 | A kind of traditional Chinese medicine compound composition and application with regulating immune function |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111557968A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113995820A (en) * | 2021-09-01 | 2022-02-01 | 湖南鹍廷科技开发有限责任公司 | Chinese medicinal preparation for treating malignant tumor and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1403147A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for raising body's immunity and its prepn |
US20050227910A1 (en) * | 2000-12-18 | 2005-10-13 | Yang David J | Local regional chemotherapy and radiotherapy using in situ hydrogel |
CN1868485A (en) * | 2005-05-24 | 2006-11-29 | 山东绿叶天然药物研究开发有限公司 | Medicine composition and its application |
CN101224220A (en) * | 2008-01-24 | 2008-07-23 | 上海中药创新研究中心 | Compounds for strengthening organism immunity function and application thereof |
CN103301174A (en) * | 2013-04-12 | 2013-09-18 | 吉林大学 | Composite lucid ganoderma and ginseng extract as well as preparation method and application thereof |
CN105560266A (en) * | 2014-10-15 | 2016-05-11 | 淮安信息职业技术学院 | Scutellaria barbata polysaccharide antitumor mechanism detection research method |
-
2020
- 2020-03-17 CN CN202010187232.8A patent/CN111557968A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050227910A1 (en) * | 2000-12-18 | 2005-10-13 | Yang David J | Local regional chemotherapy and radiotherapy using in situ hydrogel |
CN1403147A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for raising body's immunity and its prepn |
CN1868485A (en) * | 2005-05-24 | 2006-11-29 | 山东绿叶天然药物研究开发有限公司 | Medicine composition and its application |
CN101224220A (en) * | 2008-01-24 | 2008-07-23 | 上海中药创新研究中心 | Compounds for strengthening organism immunity function and application thereof |
CN103301174A (en) * | 2013-04-12 | 2013-09-18 | 吉林大学 | Composite lucid ganoderma and ginseng extract as well as preparation method and application thereof |
CN105560266A (en) * | 2014-10-15 | 2016-05-11 | 淮安信息职业技术学院 | Scutellaria barbata polysaccharide antitumor mechanism detection research method |
Non-Patent Citations (9)
Title |
---|
南京中医药大学: "《中药大辞典》", 30 June 2016, 上海科学技术出版社 * |
张俊佳 等: "灵芝黄芪复配物提高环磷酰胺对荷瘤小鼠的疗效", 《上海大学学报》 * |
张胜杰: "《提高免疫力最佳方案》", 30 April 2006, 河北科学技术出版社 * |
杨俊杰 等: "《中药化学实用技术》", 31 January 2016, 重庆大学出版社 * |
杨金明 等: "黄芪对S180荷瘤小鼠的免疫增强及抑瘤作用", 《中国实验临床免疫学杂志》 * |
赵余庆: "《中药及天然产物提取制备关键技术》", 31 January 2012, 中国医药科技出版社 * |
赵莲芳 等: "复方黄芪多糖拮抗环磷酰胺对小鼠毒副作用的研究", 《现代医药卫生》 * |
陈长勋: "《中药药理学》", 31 January 2015, 上海世纪出版股份有限公司 * |
黄利 等: "白术水煎剂对小鼠免疫功能的影响", 《中药药理与临床》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113995820A (en) * | 2021-09-01 | 2022-02-01 | 湖南鹍廷科技开发有限责任公司 | Chinese medicinal preparation for treating malignant tumor and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111956753B (en) | Medicinal and edible traditional Chinese medicine composition as well as preparation method and application thereof | |
CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
CN111514266B (en) | Pharmaceutical composition for improving curative effect of paclitaxel rhythm chemotherapy on gastric cancer metastasis and preparation method and application thereof | |
CN111557968A (en) | A kind of traditional Chinese medicine compound composition and application with regulating immune function | |
CN102940808A (en) | Prescription medicine for treating lung cancer and preparation method | |
CN103623280A (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
CN118044611A (en) | Lung-clearing and lung-protecting nutrition product | |
CN111671864A (en) | Traditional Chinese medicine preparation for relieving bone marrow suppression caused by chemotherapy and preparation method thereof | |
CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
CN104825817B (en) | A kind of Chinese medicine preparation with antitumor action | |
CN104225295A (en) | Composition for improving sleep, and preparation method and application thereof | |
CN101129615A (en) | Caulis spatholobi oral liquid | |
CN115645451A (en) | Tibetan bath composition, tibetan bath medicament, preparation method and use method | |
CN106511915A (en) | Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis | |
CN102805810B (en) | Chinese medicinal preparation for treating acquired immune deficiency syndrome (AIDS) and preparation method thereof | |
CN110934974A (en) | Traditional Chinese medicine composition for treating lung cancer, traditional Chinese medicine preparation and preparation method thereof | |
CN104825922A (en) | Traditional Chinese medicine composition with anti-colorectal cancer activity and preparation method and application of traditional Chinese medicine composition | |
CN114617934B (en) | Detoxifying and whitening soup | |
CN118717895B (en) | A Chinese medicine composition for treating liver cancer and its preparation method | |
CN108543036A (en) | A kind of antitumor drug and preparation method thereof | |
CN108079113A (en) | A kind of pharmaceutical composition for treating the postpartum deficiency of blood and preparation method thereof | |
CN1061887C (en) | Shengxuebao-medicine for improving hematopoitic function | |
CN109620911B (en) | Traditional Chinese medicine composition capable of improving neutropenia after chemotherapy and application thereof | |
CN117379519A (en) | Traditional Chinese medicine composition for promoting hematogenesis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200821 |
|
RJ01 | Rejection of invention patent application after publication |